SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rajendra Gharbaran, Jongwhan Park, Chris Kim, A. Goy, K. Stephen Suh, Circulating tumor cells in Hodgkin's lymphoma—A review of the spread of HL tumor cells or their putative precursors by lymphatic and hematogenous means, and their prognostic significance, Critical Reviews in Oncology/Hematology, 2014, 89, 3, 404

    CrossRef

  2. 2
    Girish Venkataraman, M. Kamran Mirza, Dennis A. Eichenauer, Volker Diehl, Current status of prognostication in classical Hodgkin lymphoma, British Journal of Haematology, 2014, 165, 3
  3. 3
    Francesco Gaudio, Tommasina Perrone, Anna Mestice, Paola Curci, Annamaria Giordano, Mario Delia, Domenico Pastore, Giorgina Specchia, Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma, Leukemia & Lymphoma, 2014, 55, 7, 1596

    CrossRef

  4. 4
    Ahmed Ali Elsayed, Naoko Asano, Koichi Ohshima, Koji Izutsu, Tomohiro Kinoshita, Shigeo Nakamura, Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: A clinicopathologic study, Pathology International, 2014, 64, 7
  5. 5
    G. Venkataraman, J. Y. Song, A. Tzankov, S. Dirnhofer, G. Heinze, M. Kohl, A. Traverse-Glehen, F. C. Eberle, J. C. Hanson, M. A. Raffeld, S. Pittaluga, E. S. Jaffe, Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival, Blood, 2013, 121, 10, 1795

    CrossRef

  6. 6
    Sidonie K. Hartridge-Lambert, Heiko Schöder, Remy C. Lim, Jocelyn C. Maragulia, Carol S. Portlock, ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma, Cancer, 2013, 119, 6
  7. 7
    Lawrence M. Weiss, Atypical Phenotypes in Classical Hodgkin Lymphoma, Surgical Pathology Clinics, 2013, 6, 4, 729

    CrossRef

  8. 8
    Aisha Masood, Amir Steinberg, Erin Moshier, Adriana Malone, Eileen Scigliano, Jacqueline Nieto, Keren Osman, Celia Grosskreutz, Luis Isola, Joshua Brody, Retrospective analysis of prognosticators in patients with relapsed Hodgkin’s Lymphoma treated with autologous transplant: results of a single center, Medical Oncology, 2013, 30, 1

    CrossRef

  9. 9
    A. Younes, Y. Oki, P. McLaughlin, A. R. Copeland, A. Goy, B. Pro, L. Feng, Y. Yuan, H. H. Chuang, H. A. Macapinlac, F. Hagemeister, J. Romaguera, F. Samaniego, M. A. Fanale, B. S. Dabaja, M. A. Rodriguez, N. Dang, L. W. Kwak, S. S. Neelapu, L. E. Fayad, Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma, Blood, 2012, 119, 18, 4123

    CrossRef

  10. 10
    Luis de la Cruz-Merino, Marylène Lejeune, Esteban Nogales Fernández, Fernando Henao Carrasco, Ana Grueso López, Ana Illescas Vacas, Mariano Provencio Pulla, Cristina Callau, Tomás Álvaro, Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications, Clinical and Developmental Immunology, 2012, 2012, 1

    CrossRef

  11. 11
    Antonino Carbone, Michele Spina, Annunziata Gloghini, Umberto Tirelli, Classical Hodgkin's lymphoma arising in different host's conditions: Pathobiology parameters, therapeutic options, and outcome, American Journal of Hematology, 2011, 86, 2
  12. 12
    Mikhail Roshal, Brent L. Wood, Jonathan R. Fromm, Flow Cytometric Detection of the Classical Hodgkin Lymphoma: Clinical and Research Applications, Advances in Hematology, 2011, 2011, 1

    CrossRef

  13. 13
    Enrico Derenzini, Anas Younes, Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances, Genome Medicine, 2011, 3, 4, 26

    CrossRef

  14. 14
    K. A. Blum, Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma, Hematology, 2010, 2010, 1, 93

    CrossRef

  15. 15
    A. Younes, F. Wong, Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma, Annals of Oncology, 2009, 20, 6, 1147

    CrossRef

  16. 16
    Rodney R. Miles, Cohra C. Mankey, Charlie E. Seiler, Lauren B. Smith, Julie Teruya-Feldstein, Eric D. Hsi, Kojo S.J. Elenitoba-Johnson, Megan S. Lim, Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas, Human Pathology, 2009, 40, 12, 1731

    CrossRef

  17. 17
    Franziska C. Eberle, Haresh Mani, Elaine S. Jaffe, Histopathology of Hodgkin’s Lymphoma, The Cancer Journal, 2009, 15, 2, 129

    CrossRef

  18. 18
    Bertram Schnitzer, Hodgkin Lymphoma, Hematology/Oncology Clinics of North America, 2009, 23, 4, 747

    CrossRef

  19. 19
    Eric D. Hsi, Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment, Leukemia & Lymphoma, 2008, 49, 9, 1668

    CrossRef

  20. 20
    Vera Aldred, José Vassallo, Antônio Hugo J. Froes M. Campos, Fernando Augusto Soares, CD20 expression by Hodgkin–Reed–Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients, Leukemia & Lymphoma, 2008, 49, 11, 2198

    CrossRef

  21. 21
    Atlas of Differential Diagnosis in Neoplastic Hematopathology, Second Edition, 2008,

    CrossRef

  22. 22
    Victor Yazbeck, Georgios V Georgakis, Amanda Wedgwood, Anas Younes, Hodgkin’s lymphoma: molecular targets and novel treatment strategies, Future Oncology, 2006, 2, 4, 533

    CrossRef

  23. 23
    The Lymphomas, 2006,

    CrossRef

  24. 24
    Alexandra Traverse-Glehen, Stefania Pittaluga, Philippe Gaulard, Lynn Sorbara, Miguel A Alonso, Mark Raffeld, Elaine S Jaffe, Mediastinal Gray Zone Lymphoma, The American Journal of Surgical Pathology, 2005, 29, 11, 1411

    CrossRef

  25. 25
    Current Awareness in Hematological Oncology, Hematological Oncology, 2004, 22, 3
  26. 26
    Paul M. Barr, Jonathan W. Friedberg, Rare B Cell Lymphoproliferative Disorders,